Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Multiple Myeloma Physicians

Articles with lock require a subscription to GLG News | Request a free trial
April 10, 2008
Sickle Cell Anemia: Does Icagen, Inc have an answer in senicapoc (ICA-17043)?
Analysis of: Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia | bloodjournal.hematologylibrary.org
Author: GLG Expert Contributor
"Senicapoc, a novel Gardos channel inhibitor, limits solute and water loss, thereby preserving sickle red blood cell (RBC) hydration." This appears to decrease hemolysis and increase hemoglobin levels.
April 10, 2008
Biosimilar " Neukine" will add to Amgen woes and is just tip of the iceberg!!!
Analysis of: Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market | www.pipelinereview.com
Author: GLG Expert Contributor
An indian product similar to Amgen's Filgastrim " G-CSF" showed comparable efficacy and safety in a trial in Europe and is expected to get EMEA approval in 2010.  " Neukine" is already in use in India and in several "developing countries" in the MiddlE Esat and Asia where it is available at less...
April 10, 2008
Oncophage approval in Russia: Following Sutton's Rule!!!
Analysis of: Oncophage(R) Approved in Russia for the Treatment of Intermediate-Risk Kidney Cancer | www.pipelinereview.com
Author: GLG Expert Contributor
Antigenics' Oncophage is a form of immunotherapy for patients with intermediate risk renal cancer that showed efficacy in improving recurrence free survival in a randomized trial . The approval in Russia, may be due in addition to the obvious reason of less regulatory restrictions, is that the company...
April 9, 2008
Bexarotene (Ligand) It's SPIRIT is alive in a subset of lung cancer patients.
Analysis of: Phase III Trial Comparing Carboplatin, Paclitaxel, and Bexarotene With Carboplatin and Paclitaxel in Chemotherapy-Naïve Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer: SPIRIT II | jco.ascopubs.org
Author: GLG Expert Contributor
This study, as well as a companion paper in the same JCO (Spirit I & II) http://jco.ascopubs.org/cgi/content/full/26/11/1886 Show that the subset of patients with markedly increase in lipids, survived > 12 mo!!
April 9, 2008
Oncophage(R) : Let's wait until the results are duplicated in Costa Rica.......
Analysis of: Oncophage(R) Approved in Russia for the Treatment of Intermediate-Risk Kidney Cancer | www.pipelinereview.com
Author: GLG Expert Contributor
Antigenics Inc. (NASDAQ: AGEN) had to go to Russia to perform this clinical trial???
April 4, 2008
Genetic drivers of lung cancer risk identified.
Analysis of: Studies Find Genetic Link to Smoking | www.nytimes.com
Author: GLG Expert Contributor
Gene driven nicotine receptors will predispose to increased smoking. What will this lead to?? Increased addiction due to mutations increases cancer risk.
Charles BennettApril 4, 2008
Advantages of SenoRx Contura over Mammosite Breast Brachytherapy system.
Analysis of: A new player in the growing Breast Brachytherapy field | www.senorx.com
Author: Charles Bennett, Radiation Oncologist , Robert Boissoneault Oncology Institute
SenoRx has released the Contura system which provides a superior system when compared to the Mammosite Breast Brachytherapy System.  These advantages include: 1.  Better dosimetry, opening the door for more patients to be treated by avoiding the elimination of some patients due to skin spacing...
April 2, 2008
An unmet need still unmet, tough luck for Pfizer
Analysis of: Pfizer Ends Clinical Trial Of Melanoma Treatment | online.wsj.com
Author: GLG Expert Contributor
Drug (monoclonal ab?) failed in a phase III trial vs chemotherapy (not particularly effective.)
April 2, 2008
Hype and hope for another cancer vaccine
Analysis of: Oxford BioMedica Report Encouraging New Phase II Trial Results With TroVax(R) in Prostate Cancer | www.pipelinereview.com
Author: GLG Expert Contributor
Biological efficacy has been shown for a number of cancer vaccines. Clinical efficacy has been shown in few of them. Clinical benefit just in one: idiotype vaccine for B-cell lymphoma. TroVax still has to clear the last hurdle, and likely also the second one.
April 1, 2008
Amgen, Well at least they have Aranesp. (Whoops!)
Analysis of: Unexpected Toxicity with Panitumumab Plus Chemotherapy-Bevacizumab Combo in Colorectal Cancer | www.oncology-times.com
Author: GLG Expert Contributor
Vectibix's undue toxicity without obvious benefits punctures Amgen's hope of finding a first or even second line use for this EGFR directed monoclonal antibody.

Previous Page : 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Next171 to 180 of 889

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-05T01:45:24.617